An interventional study of Propionate clobetasol gel 0.05% and Photobiomodulation in Lichen Planus, Oral and Low-Level Light Therapy, sponsored by University of Nove de Julho. Status unknown at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-26.
Sponsored by University of Nove de Julho · Not applicable, Interventional, and Treatment
The aim of this study was to compare the efficacy of PBM (660nm) and corticosteroid therapy with clobetasol propionate 0.05% in the treatment of OLP. This is a protocol for a randomized, controlled, double blind clinical trial. Fourty-four patients will be randomized in two experimental groups. Control group will be treated with clobetasol propionate 0.05% for 30 consecutive days and with placebo PBM twice a week. The experimental group will be treated with placebo gel for 30 consecutive days to mask the treatment and patients will receive PBM twice a week during 1 month (laser λ = 660±10 nm; power 100mW; radiant energy 177J/cm2; 5-s exposure time per point and 0.5J of energy per point. The primary variable (pain) and the secondary variables including clinical scores and functional scores as well as patient anxiety and depression (The Hospital Anxiety and Depression Scale-HADS), will be evaluated at the baseline, once a week during treatment and after 30 and 60 days of follow up. Evaluation of clinical resolution will be performed at the end of the treatment (30 days). Evaluation of recurrence will be performed after 30 and 60 days of follow up. Serum and salivary levels of IL-6, IL-10, IL-1β, INF-γ and TNF-α will be evaluated at baseline and at the end of treatment (30 days). Quality of life will be evaluated by OHIP-14 questionnaire at baseline, at the end of treatment and after 30 and 60 days of follow up. The chi-square test, Student's t-test and ANOVA will be used and the level of significance of 5% will be considered (p \< 0.05).
Oral lichen planus is an idiopathic chronic mucocutaneous disease with a ride range of clinical manifestations, including white reticular patches, erosive/ulcerative and atrophic lesions, both associated with intense symptomatology. CD4+ and CD8+ T lymphocytes cells play an important role in the pathogenesis of OLP and are responsible for the production of different cytokines, including IL-6, IL-10, IL-1β, INF-γ and TNF-α. Treatment is symptomatic and topical corticosteroids are commonly used as standard therapy. However, patients frequently present relapses after treatment's discontinuation, develop resistance to corticosteroids therapy as well as secondary candidiasis. Photobiomodulation (PBM) has shown to be a potential therapeutic tool to treat inflammatory disorders, including OLP. Some studies have demonstrated that PBM improves the clinical presentation of OLP (erosive/ulcerative or atrophic lesions to reticular lesions), reduces pain and recurrence. However, it remains controversy if PBM is more effective than corticosteroid in the treatment of OLP. The aim of this study is to evaluate the efficacy of PBM in the treatment of OLP in relation to the standard therapy with corticosteroids. This is a protocol for a randomized, controlled, doubled blind clinical trial, with two months of follow up.
Patients with symptomatic OLP and with histopathological diagnosis of OLP based on WHO criteria will be included in this study. Fourty-four patients will be randomized in two experimental groups. Control group will be treated with clobetasol propionate 0.05% gel for 30 consecutive days and the laser device will be positioned over the lesion but will be switched off to mask the treatment. The experimental group will be treated with placebo gel for 30 consecutive days to mask the treatment and patients will receive laser treatment twice a week during 1 month for PBM (laser λ = 660±10 nm; power 100mW; radiant energy; 177J/cm2; 5-s exposure time per point and 0.5J of energy per point). The primary variable (pain by VAS scale) and the secondary variables (clinical scores, functional scores and Patient anxiety and depression) will be evaluated at the baseline, once a week during treatment and after 30 and 60 days of follow up. Evaluation of clinical resolution will be performed at the end of the treatment (30 days). Evaluation of recurrence will be performed after 30 and 60 days of follow up. Serum and salivary levels of IL-6, IL-10, IL-1β, INF-γ and TNF-α will be evaluated at baseline and at the end of treatment (30 days). Quality of life will be evaluated by OHIP-14 questionnaire at baseline, at the end of treatment and after 30 and 60 days of follow up. The findings will be computed and submitted to statistical analysis. Interval estimates will be used for the variables of interest to determine the prevision of the estimates and perform comparisons. If necessary, transformation methods or non-parametric tests will be applied. The chi-square test, Student's t-test and ANOVA will be used and the level of significance of 5% will be considered (p \< 0.05).
142 studies on the registry are indexed under Lichen Planus, Oral; 27 are open to participants now.
This study's planned enrollment of 44 is above the median of 39 across 101 interventional studies indexed under Lichen Planus, Oral.
Browse Lichen Planus, Oral studies →University of Nove de Julho is the lead sponsor of 246 studies on the registry; 52 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 1 (13%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ =660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
Device: Photobiomodulation · Other: Placebo gel
Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days. Laser device will be positioned over the lesion but will be switched off to mask the treatment. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
Drug: Propionate clobetasol gel 0.05% · Other: Placebo Photobiomodulation
Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days and with placebo laser twice a week. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
Also known as: Clobetasol
Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ = 660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
Also known as: Low level laser therapy
Placebo gel for 30 consecutive days to mask the treatment
Also known as: inative gel
Laser device will be positioned over the lesion but will be switched off to mask the treatment.
Also known as: Laser off
Assessment of Pain of OLP
The pain will be assessed by applying a Visual Analog Scale, consisting of a 100-mm line numbered in centimeters, with two closed ends. One end is labeled "0" and the other "100", meaning no pain and terrible pain, respectively. Each patient will be instructed to mark a vertical line according to the best value that matches the intensity of pain during the evaluation.
Time frame: Participants will be evaluated at baseline (Day 0)
Assessment of Pain of OLP
The pain will be assessed by applying a Visual Analog Scale, consisting of a 100-mm line numbered in centimeters, with two closed ends. One end is labeled "0" and the other "100", meaning no pain and terrible pain, respectively. Each patient will be instructed to mark a vertical line according to the best value that matches the intensity of pain during the evaluation.
Time frame: Participants will be evaluated after 1 week of treatment (Day 7)
Assessment of Pain of OLP
The pain will be assessed by applying a Visual Analog Scale, consisting of a 100-mm line numbered in centimeters, with two closed ends. One end is labeled "0" and the other "100", meaning no pain and terrible pain, respectively. Each patient will be instructed to mark a vertical line according to the best value that matches the intensity of pain during the evaluation.
Time frame: Participants will be evaluated after 2 weeks of treatment (Day 14)
Assessment of Pain of OLP
The pain will be assessed by applying a Visual Analog Scale, consisting of a 100-mm line numbered in centimeters, with two closed ends. One end is labeled "0" and the other "100", meaning no pain and terrible pain, respectively. Each patient will be instructed to mark a vertical line according to the best value that matches the intensity of pain during the evaluation.
Time frame: Participants will be evaluated after 3 weeks of treatment (Day 21)
Assessment of Pain of OLP
The pain will be assessed by applying a Visual Analog Scale, consisting of a 100-mm line numbered in centimeters, with two closed ends. One end is labeled "0" and the other "100", meaning no pain and terrible pain, respectively. Each patient will be instructed to mark a vertical line according to the best value that matches the intensity of pain during the evaluation.
Time frame: Participants will be evaluated after 4 weeks of treatment (Day 30)
Assessment of Pain of OLP
The pain will be assessed by applying a Visual Analog Scale, consisting of a 100-mm line numbered in centimeters, with two closed ends. One end is labeled "0" and the other "100", meaning no pain and terrible pain, respectively. Each patient will be instructed to mark a vertical line according to the best value that matches the intensity of pain during the evaluation.
Time frame: 30 days after the discontinuation of treatment (follow-up period)
Assessment of Pain of OLP
The pain will be assessed by applying a Visual Analog Scale, consisting of a 100-mm line numbered in centimeters, with two closed ends. One end is labeled "0" and the other "100", meaning no pain and terrible pain, respectively. Each patient will be instructed to mark a vertical line according to the best value that matches the intensity of pain during the evaluation.
Time frame: 60 days after the discontinuation of treatment (follow-up period)
Assessment of clinical presentation of OLP
Clinical data will be evaluated by scores according to Thongprasom et al
Time frame: Participants will be evaluated at baseline (Day 0)
Assessment of clinical presentation of OLP
Clinical data will be evaluated by scores according to Thongprasom et al
Time frame: Participants will be evaluated after 1 week of treatment (Day 7)
Assessment of clinical presentation of OLP
Clinical data will be evaluated by scores according to Thongprasom et al
Time frame: Participants will be evaluated after 2 weeks of treatment (Day 14)
Assessment of clinical presentation of OLP
Clinical data will be evaluated scores according to Thongprasom et al
Time frame: Participants will be evaluated after 3 weeks of treatment (Day 21)
Assessment of clinical presentation of OLP
Clinical data will be evaluated by scores according to Thongprasom et al
Time frame: Participants will be evaluated after 4 weeks of treatment (Day 30)
Assessment of clinical presentation of OLP
Clinical data will be evaluated by scores according to Thongprasom et al
Time frame: 30 days after the discontinuation of treatment (follow-up period)
Assessment of clinical presentation of OLP
Clinical data will be evaluated by scores according to Thongprasom et al
Time frame: 60 days after the discontinuation of treatment (follow-up period)
Function
The functional scores will be applied to evaluate chewing function, swallowing, fluid intake and altered sense of taste, according to Libelly et al (2006). Each function evaluated will receive the follow scores: 0 ( no difficulty) , 1 ( mild difficulty) , 2, ( moderate difficulty), 3, (severe difficulty), and 4 ( impossibility to perform certain function).
Time frame: Participants will be evaluated at baseline (Day 0)
Function
The functional scores will be applied to evaluate chewing function, swallowing, fluid intake and altered sense of taste, according to Libelly et al (2006). Each function evaluated will receive the follow scores: 0 ( no difficulty) , 1 ( mild difficulty) , 2, ( moderate difficulty), 3, (severe difficulty), and 4 ( impossibility to perform certain function).
Time frame: Participants will be evaluated after 1 week of treatment (Day 7)
Function
The functional scores will be applied to evaluate chewing function, swallowing, fluid intake and altered sense of taste, according to Libelly et al (2006). Each function evaluated will receive the follow scores: 0 ( no difficulty) , 1 ( mild difficulty) , 2, ( moderate difficulty), 3, (severe difficulty), and 4 ( impossibility to perform certain function).
Time frame: Participants will be evaluated after 2 weeks of treatment (Day 14)
Function
The functional scores will be applied to evaluate chewing function, swallowing, fluid intake and altered sense of taste, according to Libelly et al (2006). Each function evaluated will receive the follow scores: 0 ( no difficulty) , 1 ( mild difficulty) , 2, ( moderate difficulty), 3, (severe difficulty), and 4 ( impossibility to perform certain function).
Time frame: Participants will be evaluated after 3 weeks of treatment (Day 21)
Function
The functional scores will be applied to evaluate chewing function, swallowing, fluid intake and altered sense of taste, according to Libelly et al (2006). Each function evaluated will receive the follow scores: 0 ( no difficulty) , 1 ( mild difficulty) , 2, ( moderate difficulty), 3, (severe difficulty), and 4 ( impossibility to perform certain function).
Time frame: Participants will be evaluated after 4 weeks of treatment (Day 30)
Function
The functional scores will be applied to evaluate chewing function, swallowing, fluid intake and altered sense of taste, according to Libelly et al (2006). Each function evaluated will receive the follow scores: 0 ( no difficulty) , 1 ( mild difficulty) , 2, ( moderate difficulty), 3, (severe difficulty), and 4 ( impossibility to perform certain function).
Time frame: 30 days after the discontinuation of treatment (follow-up period)
Function
The functional scores will be applied to evaluate chewing function, swallowing, fluid intake and altered sense of taste, according to Libelly et al (2006). Each function evaluated will receive the follow scores: 0 ( no difficulty) , 1 ( mild difficulty) , 2, ( moderate difficulty), 3, (severe difficulty), and 4 ( impossibility to perform certain function).
Time frame: 60 days after the discontinuation of treatment (follow-up period)
Clinical Resolution
The clinical resolution will be evaluated at the end of treatment (day 30) according to Corozzo et al. (1999). Complete resolution will be considered when patients present absence of symptoms and remission of atrophic/erosive lesions regardless the presence of any persisting hyperkeratotic lesions. Partial resolution will be considered when a decrease but not the complete remission of atrophic/erosive areas and symptoms were observed. No response to treatment will be considered when OLP lesions present the same clinical or worse presentation in relation to the baseline condition.
Time frame: Participants will be evaluated after 4 weeks of treatment (Day 30)
Recurrence rate
No recurrence will be considered when the patient presents the same clinical aspect of lesion at the end of treatment and recurrence, when the patient present new atrophic/erosive lesion at the same site during the follow-up period.
Time frame: The recurrence rate will be evaluated 30 days after the discontinuation of treatment (follow-up period)
Recurrence rate
No recurrence will be considered when the patient presents the same clinical aspect of lesion at the end of treatment and recurrence, when the patient present new atrophic/erosive lesion at the same site during the follow-up period.
Time frame: The recurrence rate will be evaluated 60 days after the discontinuation of treatment (follow-up period)
Salivary levels of IL-1β, IL-6, IL-8, IL-10 and TNFα
The samples will be centrifuged and stored at -80°C. Salivary levels of IL-6, IL-10, IL-1β, INF-γ and TNF-α will be evaluated by Enzyme Linked Immune Sorbent Assay (ELISA), according to manufacturer's instructions.
Time frame: Baseline (day 0)
Salivary levels of IL-1β, IL-6, IL-8, IL-10 and TNFα
The samples will be centrifuged and stored at -80°C. Salivary levels of IL-6, IL-10, IL-1β, INF-γ and TNF-α will be evaluated by Enzyme Linked Immune Sorbent Assay (ELISA), according to manufacturer's instructions.
Time frame: After 4 weeks of treatment (Day 30)
Serum levels of IL-1β, IL-6, IL-8, IL-10 and TNFα
Peripheral blood will be centrifuged at 400xg for 10 min at 4°C. Serum will be collected and stored at -80°C. Serum levels of IL-6, IL-10, IL-1β, INF-γ and TNF-α will be evaluated by Enzyme Linked Immune Sorbent Assay (ELISA), according to manufacturer's instructions.
Time frame: Baseline (Day 0)
Serum levels of IL-1β, IL-6, IL-8, IL-10 and TNFα
Peripheral blood will be centrifuged at 400xg for 10 min at 4°C. Serum will be collected and stored at -80°C. Serum levels of IL-6, IL-10, IL-1β, INF-γ and TNF-α will be evaluated by Enzyme Linked Immune Sorbent Assay (ELISA), according to manufacturer's instructions.
Time frame: After 4 weeks of treatment (Day 30)
Assessment of Quality of life in OLP patients
Patient quality of life will be measured by means of the Oral Health Impact Profile (OHIP 14)
Time frame: Baseline (Day 0)
Assessment of Quality of life in OLP patients
Patient quality of life will be measured by means of the Oral Health Impact Profile (OHIP 14)
Time frame: After 4 weeks of treatment (Day 30)
Assessment of Quality of life in OLP patients
Patient quality of life will be measured by means of the Oral Health Impact Profile (OHIP 14)
Time frame: 30 days after the discontinuation of treatment (follow-up period)
Assessment of Quality of lifein OLP patients
Patient quality of life will be measured by means of the Oral Health Impact Profile (OHIP 14)
Time frame: 60 days after the discontinuation of treatment (follow-up period)
Anxiety and Depression
Patient anxiety and depression will be measured by means of The Hospital Anxiety and Depression Scale (HADS)
Time frame: Baseline (Day 0)
Anxiety and Depression
Patient anxiety and depression will be measured by means of The Hospital Anxiety and Depression Scale (HADS)
Time frame: Participants will be evaluated after 1 week of treatment (Day 7)
Anxiety and Depression
Patient anxiety and depression will be measured by means of The Hospital Anxiety and Depression Scale (HADS)
Time frame: Participants will be evaluated after 2 weeks of treatment (Day 14)
Anxiety and Depression
Patient anxiety and depression will be measured by means of The Hospital Anxiety and Depression Scale (HADS)
Time frame: Participants will be evaluated after 3 weeks of treatment (Day 21)
Anxiety and Depression
Patient anxiety and depression will be measured by means of The Hospital Anxiety and Depression Scale (HADS)
Time frame: Participants will be evaluated after 4 weeks of treatment (Day 30)
Anxiety and Depression
Patient anxiety and depression will be measured by means of The Hospital Anxiety and Depression Scale (HADS)
Time frame: 30 days after the discontinuation of treatment (follow-up period)
Anxiety and Depression
Patient anxiety and depression will be measured by means of The Hospital Anxiety and Depression Scale (HADS)
Time frame: 60 days after the discontinuation of treatment (follow-up period)
Plan to share: No
Started Nov 2018 (actual). Primary completion is estimated for Nov 2020, 24 months after the start.
Of 20 interventional studies with no phase under Lichen Planus, Oral, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's planned 24 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.